NO20013115L - En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes - Google Patents

En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes

Info

Publication number: NO20013115L
Authority: NO; Norway
Prior art keywords: diabetes; treatment; combination; insulin; insulin sensitizers
Prior art date: 1998-12-24

Application number

NO20013115A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013115D0 (no

Inventor

Mark D Erion

Paul Van Poelje

Original Assignee

Metabasis Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-24

Filing date

2001-06-21

Publication date

2001-08-24

2001-06-21 Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc

2001-06-21 Publication of NO20013115D0 publication Critical patent/NO20013115D0/no

2001-08-24 Publication of NO20013115L publication Critical patent/NO20013115L/no

Links

101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 title abstract 2
101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 title abstract 2
101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 title abstract 2
101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 title abstract 2
101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 title abstract 2
229940122355 Insulin sensitizer Drugs 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

NO20013115A 1998-12-24 2001-06-21 En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes NO20013115L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11471898P	1998-12-24	1998-12-24
PCT/US1999/030713 WO2000038666A2 (fr)	1998-12-24	1999-12-22	COMBINAISON D'INHIBITEURS DE LA FBPase ET DE SENSIBILISANTS A L'INSULINE, POUR LE TRAITEMENT DU DIABETE

Publications (2)

Publication Number	Publication Date
NO20013115D0 NO20013115D0 (no)	2001-06-21
NO20013115L true NO20013115L (no)	2001-08-24

Family

ID=22357016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013115A NO20013115L (no)	1998-12-24	2001-06-21	En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes

Country Status (25)

Country	Link
EP (1)	EP1143955B1 (fr)
JP (1)	JP2003515523A (fr)
KR (3)	KR100689943B1 (fr)
CN (3)	CN1714866A (fr)
AT (1)	ATE300288T1 (fr)
AU (1)	AU771039B2 (fr)
BR (1)	BR9917005A (fr)
CA (1)	CA2354053A1 (fr)
CZ (1)	CZ20012353A3 (fr)
DE (1)	DE69926400T2 (fr)
DK (1)	DK1143955T3 (fr)
ES (1)	ES2246586T3 (fr)
HK (1)	HK1046863B (fr)
HU (1)	HUP0402506A3 (fr)
ID (1)	ID30237A (fr)
IL (2)	IL143569A0 (fr)
MX (1)	MXPA01006511A (fr)
NO (1)	NO20013115L (fr)
NZ (1)	NZ512219A (fr)
PL (1)	PL352756A1 (fr)
PT (1)	PT1143955E (fr)
RU (2)	RU2227749C2 (fr)
SK (1)	SK9172001A3 (fr)
WO (1)	WO2000038666A2 (fr)
ZA (1)	ZA200105016B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998039344A1 (fr)	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
US6312662B1 (en)	1998-03-06	2001-11-06	Metabasis Therapeutics, Inc.	Prodrugs phosphorus-containing compounds
PT1112275E (pt)	1998-09-09	2003-12-31	Metabasis Therapeutics Inc	Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
MXPA02006156A (es)	1999-12-22	2003-09-22	Metabasis Therapeutics Inc	Nuevos profarmacos de bisamidato fosfonato.
CA2401706A1 (fr)	2000-03-08	2001-09-13	Metabasis Therapeutics, Inc.	Nouveaux inhibiteurs de la fructose-1,6-biophosphatase, a base d'aryle
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CZ20035A3 (cs) *	2000-07-06	2003-05-14	Metabasis Therapeutics, Inc.	Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes
WO2002040458A1 (fr) *	2000-11-17	2002-05-23	Takeda Chemical Industries, Ltd.	Derives d'isoxazole
US7214668B2 (en)	2002-05-13	2007-05-08	Metabasis Therapeutics, Inc.	Phosphonic acid based prodrugs of PMEA and its analogues
NZ536327A (en)	2002-05-13	2007-08-31	Metabasis Therapeutics Inc	PMEA and PMPA cyclic producing synthesis
EP1534314B1 (fr) *	2002-09-04	2014-10-22	DSM IP Assets B.V.	Composition nutritionnelle et thérapeutique d'un agent sensibilisant à l'insuline et d'une fraction peptidique
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EA009919B1 (ru) *	2003-02-11	2008-04-28	Вернэлис (Кембридж) Лимитед	Соединения изоксазола
CN1902196B (zh)	2003-12-26	2010-12-29	协和发酵麒麟株式会社	噻唑衍生物
CN101005847A (zh) *	2004-08-18	2007-07-25	症变治疗公司	果糖1,6－双磷酸酶的新颖噻唑类抑制剂
CA2590883A1 (fr) *	2004-12-13	2006-06-22	Daiichi Sankyo Company, Limited	Composition medicinale pour le traitement du diabete
TW200633702A (en) *	2004-12-15	2006-10-01	Sankyo Co	Medicinal composition containing fbpase inhibitor
WO2006126673A1 (fr) *	2005-05-27	2006-11-30	Daiichi Sankyo Company, Limited	Médicament combiné pour le traitement du diabète
JPWO2006137527A1 (ja)	2005-06-23	2009-01-22	協和発酵キリン株式会社	チアゾール誘導体
WO2008057933A2 (fr)	2006-11-02	2008-05-15	Aestus Therapeutics, Inc.	Procédés de traitement de la douleur neuropathique par la modulation des voies de la glycogénolyse ou de la glycolyse
CN103665043B (zh)	2012-08-30	2017-11-10	江苏豪森药业集团有限公司	一种替诺福韦前药及其在医药上的应用
US9631825B2 (en)	2012-12-18	2017-04-25	Nortek Air Solutions, Llc	Air filter assembly
EP3105238A4 (fr)	2014-02-13	2017-11-08	Ligand Pharmaceuticals, Inc.	Composés de promédicaments et leurs utilisations
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
CN105481896A (zh) *	2015-12-03	2016-04-13	浙江大学	一种地马格列的制备方法
CN113416739B (zh) *	2021-06-24	2022-04-19	黑龙江八一农垦大学	鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968790A (en) *	1988-08-12	1990-11-06	American Cyanamid Company	Antidiabetic phosphates
JPH03157377A (ja) *	1988-11-18	1991-07-05	Takeda Chem Ind Ltd	チオ尿素誘導体及びａｇｅ生成阻害剤
ATE114474T1 (de) *	1989-01-24	1994-12-15	Gensia Pharma	Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) *	1997-02-19	1999-01-12	Warner-Lambert Company	Sulfonylurea-glitazone combinations for diabetes
WO1998039342A1 (fr) *	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase
WO1998039344A1 (fr) *	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
WO1998039343A1 (fr) *	1997-03-07	1998-09-11	Metabasis Therapeutics, Inc.	Nouveaux inhibiteurs de benzimidazole de fructose-1,6-bisphosphatase

1999
- 1999-12-22 DK DK99964313T patent/DK1143955T3/da active
- 1999-12-22 CN CNA2005100806150A patent/CN1714866A/zh active Pending
- 1999-12-22 SK SK917-2001A patent/SK9172001A3/sk unknown
- 1999-12-22 PT PT99964313T patent/PT1143955E/pt unknown
- 1999-12-22 DE DE69926400T patent/DE69926400T2/de not_active Expired - Lifetime
- 1999-12-22 BR BR9917005-1A patent/BR9917005A/pt not_active Application Discontinuation
- 1999-12-22 ES ES99964313T patent/ES2246586T3/es not_active Expired - Lifetime
- 1999-12-22 ID IDW00200101612A patent/ID30237A/id unknown
- 1999-12-22 KR KR1020017008102A patent/KR100689943B1/ko not_active Expired - Fee Related
- 1999-12-22 HK HK02108475.5A patent/HK1046863B/zh not_active IP Right Cessation
- 1999-12-22 CN CNB998163562A patent/CN100352505C/zh not_active Expired - Fee Related
- 1999-12-22 MX MXPA01006511A patent/MXPA01006511A/es active IP Right Grant
- 1999-12-22 AU AU20583/00A patent/AU771039B2/en not_active Ceased
- 1999-12-22 EP EP99964313A patent/EP1143955B1/fr not_active Expired - Lifetime
- 1999-12-22 JP JP2000590620A patent/JP2003515523A/ja active Pending
- 1999-12-22 CZ CZ20012353A patent/CZ20012353A3/cs unknown
- 1999-12-22 HU HU0402506A patent/HUP0402506A3/hu active IP Right Revival
- 1999-12-22 CA CA002354053A patent/CA2354053A1/fr not_active Abandoned
- 1999-12-22 WO PCT/US1999/030713 patent/WO2000038666A2/fr not_active Ceased
- 1999-12-22 KR KR1020067022095A patent/KR20060114724A/ko not_active Ceased
- 1999-12-22 NZ NZ512219A patent/NZ512219A/xx not_active IP Right Cessation
- 1999-12-22 PL PL99352756A patent/PL352756A1/xx not_active Application Discontinuation
- 1999-12-22 CN CNA2007101628889A patent/CN101164618A/zh active Pending
- 1999-12-22 IL IL14356999A patent/IL143569A0/xx active IP Right Grant
- 1999-12-22 AT AT99964313T patent/ATE300288T1/de active
- 1999-12-22 RU RU2001120726/15A patent/RU2227749C2/ru not_active IP Right Cessation
- 1999-12-22 KR KR1020077008649A patent/KR20070046210A/ko not_active Ceased
2001
- 2001-06-05 IL IL143569A patent/IL143569A/en not_active IP Right Cessation
- 2001-06-19 ZA ZA200105016A patent/ZA200105016B/en unknown
- 2001-06-21 NO NO20013115A patent/NO20013115L/no not_active Application Discontinuation
2003
- 2003-10-31 RU RU2003132054/14A patent/RU2003132054A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2003515523A (ja)	2003-05-07
ID30237A (id)	2001-11-15
KR100689943B1 (ko)	2007-03-08
BR9917005A (pt)	2002-04-02
IL143569A0 (en)	2002-04-21
CZ20012353A3 (cs)	2001-12-12
DK1143955T3 (da)	2005-11-14
KR20010099942A (ko)	2001-11-09
CN1350466A (zh)	2002-05-22
CA2354053A1 (fr)	2000-07-06
ZA200105016B (en)	2002-09-19
CN100352505C (zh)	2007-12-05
DE69926400T2 (de)	2006-05-24
ES2246586T3 (es)	2006-02-16
AU2058300A (en)	2000-07-31
PL352756A1 (en)	2003-09-08
SK9172001A3 (en)	2002-04-04
NZ512219A (en)	2004-12-24
WO2000038666A3 (fr)	2001-11-29
KR20060114724A (ko)	2006-11-07
CN1714866A (zh)	2006-01-04
EP1143955A3 (fr)	2002-08-28
KR20070046210A (ko)	2007-05-02
RU2227749C2 (ru)	2004-04-27
ATE300288T1 (de)	2005-08-15
WO2000038666A2 (fr)	2000-07-06
HK1046863A1 (zh)	2003-01-30
CN101164618A (zh)	2008-04-23
RU2003132054A (ru)	2005-04-20
PT1143955E (pt)	2005-11-30
AU771039B2 (en)	2004-03-11
HUP0402506A3 (en)	2007-05-29
NO20013115D0 (no)	2001-06-21
HUP0402506A2 (hu)	2005-04-28
HK1046863B (zh)	2008-07-25
MXPA01006511A (es)	2004-03-19
EP1143955A2 (fr)	2001-10-17
EP1143955B1 (fr)	2005-07-27
IL143569A (en)	2006-06-11
DE69926400D1 (de)	2005-09-01

Publication	Publication Date	Title
NO20013115D0 (no)	2001-06-21	En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
MY169308A (en)	2019-03-21	Treatment of tnf? related disorders
IL157821A0 (en)	2004-03-28	Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
PT1112275E (pt)	2003-12-31	Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
NO20061736L (no)	1999-08-20	Krystallform av epotilon B
BR0308928A (pt)	2005-01-04	Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
MY180762A (en)	2020-12-08	Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
NO20055832L (no)	2006-02-03	Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
SG146653A1 (en)	2008-10-30	Methods and reagents for the treatment of immunoinflammatory disorders
DK1426054T3 (da)	2011-12-12	Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
TNSN06397A1 (en)	2008-02-22	Pyrazole derivatives, compositions containing such compounds and methods of use
NO20045056L (no)	2005-02-16	Fremgangsmater for behandling av hepatitt
SI1427409T1 (sl)	2009-02-28	Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (pl)	2009-12-31	Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
TNSN07372A1 (en)	2009-03-17	Method of treating or preventing type - 2 diabetes
WO2003035048A3 (fr)	2003-10-09	Procedes et compositions de traitement de l'osteo-arthrite
NO20003813L (no)	2000-07-25	FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav
NO20030021L (no)	2003-03-03	Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DE69924385D1 (de)	2005-04-28	Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date	Code	Title	Description
2010-07-19	FC2A	Withdrawal, rejection or dismissal of laid open patent application